Avience Biomedicals IPO Details
SME
Avience Biomedicals IPO DRHP (Draft Red Herring Prospectus) has been Exchange Approval Received.
Avience Biomedicals IPO total issue size comprises 16,08,000 shares (aggregating up to ₹0.00 Cr.). This includes a fresh issue of 16,08,000 shares (aggregating up to ₹0.00 Cr.). Pre-issue shareholding stands at 40,31,256, which will increase to 56,39,256 post-issue.
The Lead Managers for Avience Biomedicals IPO are crucial for the offering's success. They are responsible for a wide range of tasks, including preparing the company for the public market, managing the regulatory filings, and marketing the IPO to potential investors. The lead manager for this offering is Fintellectual Corporate Advisors Private Limited. To assess their past performance and success in previous IPOs, you can view the Lead Manager Performance Summary report.
For SME (Small and Medium-sized Enterprise) IPOs, a Market Maker is appointed to ensure liquidity and stability for the stock once it is listed. They do this by continuously quoting bid and ask prices, ensuring there is a market for the shares. The appointed market maker for this IPO is Asnani Stock Broker. You can analyze their track record by checking the Market Maker Performance Summary report.
For detailed information, Refer to the Avience Biomedicals Limited DRHP.
Avience Biomedicals IPO Details
Avience Biomedicals IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
To be announced | |||
Avience Biomedicals IPO Reservation
Promoter Holding
Documents
Avience Biomedicals IPO Valuations
Avience Biomedicals Financial Information
| Period Ended | 31 Mar 2025 | 31 Mar 2024 |
| Assets | 56.52 | 34.65 |
| Total Income | 45.97 | 24.37 |
| Profit After Tax | 7.29 | 2.15 |
| EBITDA | 11.41 | 4.08 |
| Net Worth | 22.85 | 6.23 |
| Reserves and Surplus | 18.82 | 2.94 |
| Total Borrowing | 22,15,820.00 | 15.13 |
| Amount in ₹ Crore | ||
About Avience Biomedicals IPO
Incorporated in June 2024, Avience Biomedicals Limited is an ISO certified company specializing in manufacturing, supplying, and exporting molecular diagnostic solutions, focusing on biotechnology, genomics, and the IVD industry.
Avience Biomedicals Limited has expanded its product range from IVD rapid test kits to a comprehensive line of medical devices, including serology products and biochemistry analyzers. This demonstrates a commitment to diverse healthcare needs, focusing exclusively on the B2B and B2G markets.
The company's products cater to Pathology Labs, Microbiology Labs, Hospitals, and Research Centers nationwide as well as overseas.
In addition to manufacturing, the Company also act as distributors and traders of medical equipment.
The company's manufacturing unit is situated in Noida, Uttar Pradesh.
The company offers a comprehensive range of diagnostic solutions, including:
- Rapid Test Kits: Products like AVISURE Dengue Combo Test, Malaria Rapid Test (Pf/Pv), and AVISURE Syphilis Rapid Test.
- Biochemistry Analyzers and Reagents: Devices like the BS-240 Fully Auto Analyzer and reagents like AVIENBIO Albumin Kit.
- Molecular Diagnostics: COVID-19 detection kits, including the COVID-19 Hid RTqPCR ASSAY.
- Hematology Analyzers: Models like the BC-20s 3-Part Hematology Analyzer.
- Medical Devices: Oxygen concentrators (Oxy-5 and Oxy-10) and viral transport solutions (VTM).
As of December 2024, the company had 65 permanent employees and 33 contractual employees
Competitive Strength
- Strong Industry Experience and Expertise.
- Avience provides various diagnostic products, including rapid test kits, analyzers, hematology devices, and molecular kits.
- Strong distribution network across India and is growing its international footprint.
- Cost-Effective and Affordable Solutions.
- Stringent quality control processes and complies with ISO standards and regulatory approvals.
Strength Of Avience Biomedicals IPO
Risk Of Avience Biomedicals IPO
Objectives Avience Biomedicals IPO
1. Part finances the capital expenditure towards setting up of a new manufacturing unit at industrial plot no. 70, Sector 28 in the Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh
2. Funding the working capital requirement of the company
3. General Corporate Purposes
Company Contact Details
Avience Biomedicals Ltd.
C-11, Block-C
Community Centre,
Janakpuri A-3,
Delhi, New Delhi, 110058
Phone: 1800-12-04-636
Email: info@avienbio.com
Website: https://avienbio.com/
Registrar Contact Details
Lead Mangers
Lead Manager Reports
Market Maker
Market Maker Reports
Read more about Avience Biomedicals Limited IPO
- Avience Biomedicals Limited IPO Detail
- Avience Biomedicals Limited IPO Subscription Detail
- Avience Biomedicals Limited IPO GMP Detail
- Checked Live Avience Biomedicals Limited IPO Allotment Status
- Avience Biomedicals Limited IPO Basis Of Allotment
- Avience Biomedicals Limited IPO Price Calculator
- Avience Biomedicals Limited IPO Stock Price